The disproportionately high rate of mortality compared with hormone receptor positive breast cancer or HER2 positive breast cancer is largely due to the lack of effective targeted therapies, with the exception of tumors with germline BRCA1/2 mutation3. The gene discussed is ERBB2; the disease is breast carcinoma.